The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal

Diabetic Medicine

Volumn 16, Issue 10, 1999, Pages 827-834

  Landstedt Hallin, Lena ^a   Arner, P ^b   Lins, P E ^a   Bolinder, J ^b   Olsen, H ^c   Groop, L ^c  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Combined therapy; Insulin; Sulphonylurea; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; ENZYME ANTIBODY; GLIBENCLAMIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE; INSULIN; ISOPHANE INSULIN; ISUHUMAN COMB; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN SENSITIVITY; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS ISLET CELL FUNCTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032706321     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00171.x     Document Type: Article

References (27)

1. 1 Gerich J. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-1245.
2. 2 Cull CA, Holman RR. Treatment of NIDDM - progressive requirement for polypharmacy to attain glycaemic goals. Diabetologia 1997; 40: A347.
3. 3 Riddle MC, Gard T, Hart J. A new regimen for type II diabetes: Bedtime NPH insulin with daytime sulfonylurea [Abstract]. Diabetes 1984; 33: 182A.
4. 4 Group L, Harno K, Tulppanen EM. The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta Endocrinol 1984; 106: 97-101.
5. 5 Falko JM, Osci K. Combination insulin/glyburide therapy in type II diabetes mellitus - effects on lipoprotein metabolism and glucoregulation. Am J Med 1985; 79: 92-101.
6. 6 Casner PR. Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial. Clin Pharmacol Therapeutics 1988; 44: 594-603.
7. 7 Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Mavjanen T, Niskanen L et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433.
8. 8 Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-314.
9. 9 Clauson P, Karlander S, Steen L, Efendie S. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Diabetic Med 1996; 13: 471-477.
10. 10 Shank ML, Del Prato S, De Fronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995; 44: 165-172.
11. 11 Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins P. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18: 1183-1186.
12. 12 Riddle MC, Schneider J, Group TGC. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998; 21: 1052-1057.
13. 13 Yki-Järvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.
14. 14 Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991; 115: 45-53.
15. 15 Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992; 15: 953-959.
16. 16 Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A metaanalysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-264.
17. 17 Groop LC, Groop PH, Stenman S. Combined insulin-sulfonylurea therapy in treatment of NIDDM. Diabetes Care 1990; 3: 47-52.
18. 18 Lewitt MS, Yu VK, Rennie GC, Carter JN, Marel GM, Yue DK et al. Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care 1989; 12: 379-383.
19. 19 Alford FP, Martin FI, Pearson MJ. The significance and interpretation of mildly abnormal oral glucose tolerance. Diabetologia 1971; 7: 173-180.
20. 20 Nakagawa S, Nakayama H, Sasaki T. A simple method for the determination of serum free insulin in insulin treated patients. Diabetes 1973; 22: 590-600.
21. 21 Matthews DR, Hosker JP, Rudenski AS, Naylor RA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. 22 Falorni A, Grubin CE, Takei I et al. Radioimmunoassay detects the frequent occurrence of autoantibodies to the Mr 65,000 isoform of glutamic acid decarboxylase in Japanese insulin-dependent diabetes. Autoimmunity 1994; 19: 113-125.
23. 23 Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Tyoe 2 diabetes mellitus. Diabetologia 1999; 42: 406-412.
24. 24 Welle S, Nair KS, Lockwood D. Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus. J Clin Endocrinol Metab 1988; 66: 593-597.
25. 25 Groop L, Widen E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin C et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 599-605.
26. 26 Lardinois CK, Liu GC, Reaven GM. Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone. Arch Intern Med 1985; 145: 1028-1032.
27. 27 Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 1989; 12: 623-629.